[18F]F-DOPA Imaging in Patients With Autonomic Failure (https://clinicaltrials.gov/study/NCT04246437)

Trial number: NCT04246437

Overview: This study is investigating changes in dopamine production in the brain using a special imaging technique called [18F]F-DOPA PET scan to better understand and predict progression in patients with autonomic failure and related disorders like Parkinson’s disease, Multiple System Atrophy, and Dementia with Lewy Bodies. Participants will receive oral medications before the scan and then undergo a detailed brain imaging session.

Who can participate: Adults aged 18 and older who have pure autonomic failure, autonomic failure with possible Parkinson’s disease, Multiple System Atrophy, or Dementia with Lewy Bodies, as well as healthy adults, may join if they meet clinical exam requirements and do not have certain implants, metal in their body, pregnancy, or conditions affecting consent.

Where the study is taking place: The study is being conducted at Vanderbilt University Medical Center in Nashville, Tennessee, United States.

Study timeline: The study began in February 2020 and is currently recruiting participants, aiming to enroll about 40 people, with estimated completion in February 2027. The record does not specify how long each participant will be involved.

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) (https://clinicaltrials.gov/study/NCT06868628)

Trial number: NCT06868628

Overview: This study is testing a nasal spray called Foralumab, an antibody treatment, in people with Multiple System Atrophy (MSA) to learn more about its effects; participants will use the spray three times a week for two weeks in each 3-week cycle, completing eight cycles in total. 

Who can participate: Adults aged 30 to 85 with a clinical diagnosis of MSA who meet specific health and treatment stability criteria can join; certain health conditions and recent treatments may exclude participation. 

Where the study is taking place: The study is recruiting participants at Brigham and Women’s Hospital in Boston, Massachusetts, United States. 

Study timeline: Recruitment is currently open with an estimated enrollment of 5 participants; the study started in May 2025 and is expected to complete by April 2027.

A Study of Pyridostigmine in Postural Tachycardia Syndrome (https://clinicaltrials.gov/study/NCT00409435)

Trial number: NCT00409435

Overview: This study is testing whether the drug pyridostigmine, taken once daily for three days, affects symptoms and heart rate in people with postural tachycardia syndrome (POTS), a condition causing rapid heartbeat and other symptoms when standing. Participants will have medical exams, answer symptom questionnaires, and undergo tests measuring heart rate, blood pressure, sweating, and hormone levels during two visits.

Who can participate: People aged 15 to 55 diagnosed with POTS based on specific heart rate and symptom criteria may join; pregnant or lactating women, those with certain medical conditions, or recent pyridostigmine use are excluded.

Where the study is taking place: The study is recruiting participants at the Mayo Clinic in Rochester, Minnesota, United States.

Study timeline: The study began in October 2006 and is estimated to complete in February 2027, aiming to enroll about 50 participants; recruitment is currently open.

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy (https://clinicaltrials.gov/study/NCT06568237)

Trial number: NCT06568237

Overview: This study is testing whether the oral drug TEV-56286 can help treat adults with Multiple System Atrophy (MSA), a neurological condition, by comparing it to a placebo; researchers will also assess the drug’s safety and specific effects. 

Who can participate: Adults aged 30 to 75 with a diagnosis of possible or probable MSA who are medically and psychiatrically stable may join; women of childbearing potential and men with fertile partners must use effective birth control. 

Where the study is taking place: The study is recruiting participants at multiple sites in the United States, France, Germany, Israel, Italy, Japan, Serbia, and Spain. 

Study timeline: Recruitment is ongoing with an estimated enrollment of 350 participants; the study started in October 2024 and is expected to complete by September 2027, with each participant involved for about 56 weeks including screening, treatment, and follow-up.

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (https://clinicaltrials.gov/study/NCT07197866)

Trial number: NCT07197866

Overview: This study is testing the long-term safety and tolerability of an oral drug called TEV-56286 in adults with Multiple System Atrophy (MSA), a rare neurological condition. Participants will receive the drug and be monitored for about 100 weeks.

Who can participate: Adults aged 30 and older with MSA who completed a previous related trial and meet specific health and safety criteria can join; women of childbearing potential and their partners must use effective birth control during the study.

Where the study is taking place: The study is recruiting participants at multiple sites in the United States, France, Germany, Israel, Italy, Japan, and Spain.

Study timeline: Recruitment is ongoing with an estimated enrollment of 200 participants; the study started on September 30, 2025, and is expected to complete by May 17, 2029.

AROMA-NT: Essential Oils and Wearable TENS Device for Chronic Nausea (https://clinicaltrials.gov/study/NCT07720336)

Trial number: NCT07720336

Overview: This study is investigating how two inhaled essential oil products and a wearable nerve stimulation device may affect chronic nausea and related symptoms like anxiety, sleep, and pain in adults with longstanding nausea. Participants will first track symptoms for 2 weeks, then use the oils for 12 weeks, followed by 12 weeks using the wearable device, while completing symptom surveys.

Who can participate: Adults aged 18 or older with chronic nausea lasting more than 6 months, experiencing nausea at least 3 days a week, severe nausea, and moderate or higher anxiety can join; participants must understand English and be able to complete study tasks.

Where the study is taking place: The study is recruiting participants at Ohio State University Wexner Medical Center in Columbus, Ohio, United States.

Study timeline: Recruitment is ongoing with an estimated enrollment of 250 participants; the study started in May 2024 and is expected to complete by December 2027.

Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma (https://clinicaltrials.gov/study/NCT06747910)

Trial number: NCT06747910

Overview: This study is investigating whether cardiac autonomic dysfunction (a heart-related condition affecting automatic body functions) can be accurately diagnosed using remote heart rate monitoring and a symptom questionnaire, compared to standard in-person tests. Participants will undergo an in-person heart function test, wear a wrist biosensor for 7 days at home, and complete a symptom questionnaire.

Who can participate: Adults 18 years or older who survived acute lymphoblastic leukemia, Hodgkin’s lymphoma, or non-Hodgkin’s lymphoma, are enrolled in the St. Jude Lifetime Cohort, and are not taking beta-blocker medication; participants must understand English and be able to complete the tests.

Where the study is taking place: The study is conducted at St. Jude Children’s Research Hospital in Memphis, Tennessee, United States.

Study timeline: The study is currently recruiting, aims to enroll about 188 participants, started in February 2025, and is expected to complete primary data collection by December 2026 and overall by June 2027.

Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome (https://clinicaltrials.gov/study/NCT05212129)

Trial number: NCT05212129

Overview: This study is investigating whether two types of non-invasive vagal nerve stimulation therapies can reduce gastrointestinal symptoms and improve autonomic nervous system regulation in children with hypermobile Ehlers-Danlos Syndrome (hEDS) and related conditions. Researchers will also examine nerve function and stomach movement using special tests.

Who can participate: Children aged 10 to 18 years old with functional upper gastrointestinal complaints and suspected hEDS or autonomic nervous system dysfunction may join, provided they meet specific health criteria and can communicate in English; parental consent is required.

Where the study is taking place: The study is being conducted at the Medical College of Wisconsin in Milwaukee, Wisconsin, United States.

Study timeline: The study began in April 2021 and is currently recruiting participants, aiming to enroll about 90 children, with estimated completion by December 2026.

Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies (https://clinicaltrials.gov/study/NCT06683365)

Trial number: NCT06683365

Overview: This study is testing the safety and feasibility of implanting a participant’s own nerve tissue from the leg into a specific brain area called the substantia nigra to explore potential effects on Parkinson’s disease or Multiple System Atrophy. Participants will either receive the nerve graft or a sham surgery and will be followed for one year after surgery.

Who can participate: Adults aged 40 to 75 diagnosed with Parkinson’s disease or Multiple System Atrophy for more than two years, with mild to moderate symptoms, and who can safely undergo surgery and required assessments.

Where the study is taking place: The study is recruiting participants at the University of Kentucky in Lexington, Kentucky, United States.

Study timeline: The study started in February 2025, aims to enroll about 7 participants, and expects to complete primary data collection by December 2028 and the entire study by December 2030.

Autonomic Dysfunction in Patients Following Bariatric Surgery: The ADiPOSE Study (https://clinicaltrials.gov/study/NCT06289413)

Trial number: NCT06289413

Overview: This study is observing how often and why autonomic dysfunction (a condition affecting automatic body functions like blood pressure) occurs in patients after bariatric surgery, by collecting and analyzing patient data before and after surgery.

Who can participate: Adults aged 18 to 85 who have had or will have bariatric surgery (such as gastric bypass or sleeve gastrectomy), can give consent, and continue follow-up with their surgery team; people who are pregnant, breastfeeding, or have certain health conditions are excluded.

Where the study is taking place: The study is recruiting participants at multiple medical centers and clinics in Overland Park, Kansas, and Kansas City and Independence, Missouri, United States.

Study timeline: The study began in February 2024 and is estimated to complete in December 2025, aiming to enroll about 400 participants; recruitment is currently ongoing.

Autonomic Reactivity and Personalized Neurostimulation (https://clinicaltrials.gov/study/NCT06863207)

Trial number: NCT06863207

Overview: This study is investigating how a non-invasive nerve stimulation device combined with hypnotherapy might help children with certain gut-brain disorders and symptoms linked to nervous system imbalance by measuring and adjusting treatment based on real-time nervous system activity.

Who can participate: Girls aged 11 to 18 who speak English and have specific chronic gut and nervous system symptoms, including cyclic vomiting or functional dyspepsia, without other organic diseases or severe mental health issues, may be eligible.

Where the study is taking place: The study is being conducted at the Medical College of Wisconsin in Milwaukee, Wisconsin, United States.

Study timeline: The study is currently recruiting, plans to enroll about 120 participants, started in January 2025, and is expected to complete primary data collection by December 2028 and overall completion by June 2029.

Aveir DR Real-World Evidence Post-Approval Study (https://clinicaltrials.gov/study/NCT05935007)

Trial number: NCT05935007

Overview: This study is examining the long-term safety of the Aveir DR leadless pacemaker by analyzing real-world data from patients who have received the device, to meet FDA approval requirements. No new device procedures will be done as part of the study.

Who can participate: Adults aged 18 and older who have been implanted with the Aveir DR leadless pacemaker and have continuous Medicare Part A and B coverage before and shortly after implantation are included.

Where the study is taking place: The study is recruiting participants at Abbott in Sylmar, California, United States.

Study timeline: The study began in October 2023, is currently recruiting, aims to enroll about 1,805 participants, and is expected to complete by December 2030.

Biospecimen Repository for Cardiac Arrhythmias at the Cleveland Clinic (https://clinicaltrials.gov/study/NCT00921986)

Trial number: NCT00921986

Overview: This study is creating a collection of blood and tissue samples from people with heart rhythm problems (arrhythmias) and from people without these problems to help researchers find genes and biological processes involved in arrhythmias and related conditions.

Who can participate: Adults aged 18 and older who have or have had cardiac arrhythmias, family members of those with arrhythmias, or healthy volunteers without arrhythmias can join; people already enrolled in this biobank cannot participate again.

Where the study is taking place: The study is being conducted at the Cleveland Clinic Foundation in Cleveland, Ohio, United States.

Study timeline: The study began in March 2009 and is currently recruiting participants, aiming to enroll about 2,000 people, with estimated completion in December 2035.

Blood Pressure Effects on Cognition and Brain Blood Flow in PD (https://clinicaltrials.gov/study/NCT05400174)

Trial number: NCT05400174

Overview: This study investigates how blood pressure affects thinking and brain blood flow in people with Parkinson’s disease (PD), especially those with low blood pressure when standing (orthostatic hypotension, OH). Participants will have their blood pressure and brain blood flow continuously monitored while performing thinking tests lying down and standing.

Who can participate: Adults aged 50 or older with early to moderate Parkinson’s disease who speak English and do not have dementia, severe involuntary movements, or certain medical conditions; people taking specific blood pressure or prostate medications are excluded unless they can stop these medications before the study.

Where the study is taking place: The study is being conducted at the University of California San Diego in San Diego, California, United States.

Study timeline: The study began in December 2021 and is currently recruiting; it aims to enroll about 60 participants, with estimated completion in January 2027.

Cardioneuroablation for Recurrent Vasovagal Syncope and Bradyarrhythmias: The CNA-FWRD Registry (https://clinicaltrials.gov/study/NCT06166277)

Trial number: NCT06166277

Overview: This study is observing patients with recurrent fainting (vasovagal syncope) and slow heart rhythms (bradyarrhythmias) who are treated with usual care, including medications, a procedure called cardioneuroablation (using radiofrequency to modify heart nerves), or permanent pacemaker implantation. Researchers aim to collect information on these treatments as they are used in routine practice.

Who can participate: Adults aged 18 to under 60 years who have symptoms of vasovagal syncope or bradyarrhythmias that have not improved with behavioral or medical treatments may be eligible; certain heart conditions and prior treatments exclude participation.

Where the study is taking place: The study is recruiting participants at Rush University Medical Center in Chicago, Illinois, United States.

Study timeline: Recruitment is currently open with an estimated enrollment of 300 participants; the study began in August 2024 and is expected to complete primary data collection by December 2026 and overall completion by April 2027.

Cardiovascular Function and Response to Stimulation Within the First Year After Spinal Cord Injury (https://clinicaltrials.gov/study/NCT06841198)

Trial number: NCT06841198

Overview: This study investigates how blood pressure and cardiovascular function change during the first year after a spinal cord injury and examines the effects of spinal cord transcutaneous stimulation, a non-invasive electrical stimulation applied to the spine, on blood pressure control.

Who can participate: Adults aged 18 to 75 with a recent spinal cord injury (within 7 to 50 days) at or above the T6 level, experiencing low blood pressure and orthostatic hypotension, and classified as AIS A or B; participants must be undergoing inpatient rehabilitation at the Kessler Institute and meet specific health criteria.

Where the study is taking place: The study is conducted at the Kessler Foundation in West Orange, New Jersey, United States.

Study timeline: The study is currently recruiting, plans to enroll about 15 participants, started in April 2025, and is expected to complete in November 2026; participation includes about 20-29 sessions over one year, starting during inpatient rehabilitation and continuing as outpatient visits.

CE-STAND: Cervical Epidural STimulation After Neurologic Damage (https://clinicaltrials.gov/study/NCT06410001)

Trial number: NCT06410001

Overview: This study is testing an implanted device called the Abbott Eterna epidural stimulator to see if it can improve autonomic functions (like bladder and bowel control), voluntary movement, and quality of life in people with chronic cervical spinal cord injury (SCI). Participants will have the device implanted and be assessed every three months over one year.

Who can participate: Adults aged 22 or older with stable, motor-complete cervical SCI between levels C4 and C7, who meet specific health and functional criteria, and are willing to attend all study visits may be eligible. Certain health conditions and treatments exclude participation.

Where the study is taking place: The study is recruiting participants at the University of Minnesota in Minneapolis, Minnesota, United States.

Study timeline: The study began in March 2026 and is estimated to complete by July 2030, aiming to enroll about 36 participants who will be followed for one year each.

Cereset Research Exploratory Study (https://clinicaltrials.gov/study/NCT03777267)

Trial number: NCT03777267

Overview: This study is testing Cereset Research, a device that uses audible tones reflecting brainwave activity, to see if it can improve heart and nervous system function in people with stress, anxiety, or insomnia symptoms. Participants will have 4 to 12 sessions while continuing their usual care, with measurements taken before and after treatment.

Who can participate: People aged 11 and older who have symptoms of stress, anxiety, or insomnia meeting certain questionnaire scores can join, provided they can sit still with sensors attached and do not have severe hearing loss, seizure disorders, or recent use of similar brain therapies.

Where the study is taking place: The study is recruiting participants at Wake Forest University Health Sciences in Winston-Salem, North Carolina, United States.

Study timeline: The study began in April 2019 and is currently recruiting, aiming to enroll about 200 participants, with estimated completion in April 2028. The record does not specify how long each participant will be involved.

Cereset Research for Caregivers (https://clinicaltrials.gov/study/NCT05209438)

Trial number: NCT05209438

Overview: This study is testing whether a device called Cereset Research, which uses sound tones to interact with brainwaves, can improve heart rate variability and reduce stress, anxiety, insomnia, and caregiver burden in people who care for someone with dementia.

Who can participate: Adults who provide at least 10 hours of caregiving per week, experience symptoms of stress, anxiety, or insomnia, and can attend up to three one-hour sessions per week for four weeks may join; certain health conditions and recent use of similar therapies exclude participation.

Where the study is taking place: The study is recruiting participants at Wake Forest University Health Sciences in Winston-Salem, North Carolina, United States.

Study timeline: The study began in June 2022, is currently recruiting, aims to enroll about 20 participants, and expects to complete primary data collection by July 2027 with final completion in December 2027.

Closed Loop Spinal Cord Stimulation for Complex Regional Pain Syndrome (https://clinicaltrials.gov/study/NCT06421350)

Trial number: NCT06421350

Overview: This study is investigating how a closed-loop spinal cord stimulator affects pain and function in people with complex regional pain syndrome (CRPS) when used early (acute or subacute phase) versus later (chronic phase). Participants will try a temporary stimulator for 7 days and may receive a permanent device if it helps; blood tests will measure stress-related hormone levels.

Who can participate: Adults 18 years or older with unilateral CRPS type 1 or 2 who have not had prior neuromodulation treatments and have passed psychological clearance may join.

Where the study is taking place: The study is recruiting participants at Scripps Clinic Torrey Pines in La Jolla, California, United States.

Study timeline: The study is currently recruiting, plans to enroll about 32 participants, started in September 2024, and expects to complete primary data collection and the study by June 2026.

Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain (https://clinicaltrials.gov/study/NCT04144972)

Trial number: NCT04144972

Overview: This study is testing a new type of deep brain stimulation (DBS) that adapts to brain signals to treat chronic pain that has not improved with other treatments, aiming to target multiple brain areas involved in different aspects of pain.

Who can participate: Adults aged 22 to 80 with severe, treatment-resistant chronic pain from various causes, who meet specific medical and cognitive criteria, and can understand and consent to the study.

Where the study is taking place: The study is being conducted at the University of California, San Francisco, in the United States.

Study timeline: The study began in October 2019 and is currently recruiting, with an estimated enrollment of 12 participants and an expected completion date in October 2030.

CPAP for the Treatment of Supine Hypertension (https://clinicaltrials.gov/study/NCT05489575)

Trial number: NCT05489575

Overview: This study is investigating whether continuous positive airway pressure (CPAP), a treatment that uses a machine to gently blow air through a mask, can help lower high blood pressure that occurs when lying down in people with autonomic failure. Participants will spend several days undergoing tests and using active or sham CPAP during the day and/or night to measure effects on blood pressure and heart function.

Who can participate: Adults aged 40 to 80 with autonomic failure conditions such as pure autonomic failure, multiple system atrophy, or Parkinson disease, who have a specific type of low blood pressure upon standing and high blood pressure at night while lying down, and who can provide informed consent. Certain health conditions and inability to tolerate CPAP or medication withdrawal exclude participation.

Where the study is taking place: The study is conducted at the Autonomic Dysfunction Center at Vanderbilt University Medical Center in Nashville, Tennessee, United States.

Study timeline: The study is currently recruiting and plans to enroll about 59 participants. It began in June 2022, with estimated primary completion in March 2027 and overall completion by August 2027. The ClinicalTrials.gov record does not specify how long each participant will be involved.

Data Collection of Standard Care of Patients in the EMG Section (https://clinicaltrials.gov/study/NCT05041387)

Trial number: NCT05041387

Overview: This study collects information from people with neuromuscular disorders who are not in other NIH studies by performing tests like nerve and muscle evaluations, ultrasounds, and heart and sweat measurements to build a data repository for future research.

Who can participate: Adults aged 18 and older with possible neuromuscular or neurodegenerative disorders who are able to give informed consent can join the study.

Where the study is taking place: The study is conducted at the National Institutes of Health Clinical Center in Bethesda, Maryland, United States.

Study timeline: The study is currently recruiting, aims to enroll about 200 participants, started on June 24, 2024, and is expected to complete by May 1, 2031.

Deciphering Preserved Autonomic Function After Multiple Sclerosis (https://clinicaltrials.gov/study/NCT07012135)

Trial number: NCT07012135

Overview: This study investigates how the autonomic nervous system, which controls functions like blood pressure and bladder health, works in people with multiple sclerosis by performing laboratory tests that measure the body’s ability to activate and inhibit autonomic responses.

Who can participate: Adults aged 18 to 50 with a confirmed diagnosis of multiple sclerosis or healthy individuals without injury may join, provided they do not have certain cardiovascular, respiratory, neurological, or autonomic diseases, are not pregnant or lactating, have a body mass index under 35, and meet other safety criteria.

Where the study is taking place: The study is being conducted at the Mayo Clinic in Rochester, Minnesota, United States.

Study timeline: The study is currently recruiting participants, with an estimated enrollment of 13 people; it started on September 17, 2025, and is expected to complete by December 31, 2026.

Development and Validation of the Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ) (https://clinicaltrials.gov/study/NCT06672861)

Trial number: NCT06672861

Overview: This study aims to develop and test a new questionnaire specifically for people with cardiac dysautonomia, comparing it to general health questionnaires to better understand symptoms and quality of life in this group. Participants will complete the new and established questionnaires to help researchers evaluate their usefulness.

Who can participate: Adults aged 18 and older diagnosed with postural orthostatic tachycardia syndrome (POTS), inappropriate sinus tachycardia (IST), or vasovagal syncope, without certain serious chronic health conditions, are eligible to join.

Where the study is taking place: The study will be conducted at three locations in Overland Park, Kansas, United States: Kansas City Heart Rhythm Institute, Midwest Heart and Vascular Specialists, and Overland Park Regional Medical Center.

Study timeline: The study is not yet recruiting and plans to start in January 2026, aiming to enroll about 100 participants, with completion expected by August 2026.

Differing Levels of Hypoglycemia (https://clinicaltrials.gov/study/NCT02445781)

Trial number: NCT02445781

Overview: This study is investigating how different levels of low blood sugar (hypoglycemia) affect blood vessel function and blood clotting processes in healthy adults using a controlled glucose clamp method.

Who can participate: Adults aged 18 to 55 years who are healthy, with a body mass index over 21, and without certain medical conditions or medications; pregnant women and tobacco users are excluded.

Where the study is taking place: The study is being conducted at the University of Maryland in Baltimore, Maryland, United States.

Study timeline: The study is currently recruiting, aims to enroll about 32 participants, started in July 2015, and is estimated to complete by December 2026.

Does a Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Nat hx With Its Numerous Co-morbidities? (https://clinicaltrials.gov/study/NCT06616363)

Trial number: NCT06616363

Overview: This study is investigating whether a malfunction in a brain region called the periaqueductal gray, which controls automatic body functions and pain responses, might explain Postural Orthostatic Tachycardia Syndrome (POTS) and its related conditions; participants will complete questionnaires, physical tests, brain scans, and provide biological samples to help researchers understand POTS better.

Who can participate: Female individuals aged 12 to 21 years who meet specific health criteria for POTS, recent infection, or are healthy controls, and who can use a compatible phone app; certain health conditions and other factors may exclude participation.

Where the study is taking place: The study is recruiting participants at Virginia Commonwealth University in Richmond, Virginia, United States.

Study timeline: Recruitment is currently ongoing with an estimated enrollment of 120 participants; the study started in May 2024 and is expected to complete by July 2028.

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS (https://clinicaltrials.gov/study/NCT07189936)

Trial number: NCT07189936

Overview: This study is investigating whether a drug called 2-hydroxybenzylamine (2-HOBA) can affect immune system markers and blood flow changes in people with Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS), a condition with symptoms like fatigue and rapid heartbeat upon standing. Participants will receive either 2-HOBA or a placebo for 28 days, and researchers will measure immune cell activity and blood vessel responses.

Who can participate: Adults aged 18 and older diagnosed with Long COVID lasting more than three months and POTS, characterized by specific heart rate increases upon standing, are eligible; people with certain health conditions, pregnancy, or allergies to study drugs are excluded.

Where the study is taking place: The study is recruiting participants at a site in Nashville, Tennessee, United States, specifically at the facility associated with Cyndya Shibao, MD.

Study timeline: The study began on December 18, 2025, is currently recruiting, plans to enroll about 50 participants, and expects to complete primary data collection by June 30, 2028, with overall completion by June 30, 2029.

Effect of Raised Head of the Bed on Lying Blood Pressure in Autonomic Failure (https://clinicaltrials.gov/study/NCT04502225)

Trial number: NCT04502225

Overview: This study is investigating whether raising the head of the bed can lower high blood pressure that occurs when lying down in people with autonomic failure, by reducing blood flow back to the heart using gravity.

Who can participate: Adults aged 18 to 85 with autonomic failure and supine hypertension may join, excluding pregnant women, medical students, high-risk patients, and those with serious allergies or asthma.

Where the study is taking place: The study is being conducted at Vanderbilt University Medical Center in Nashville, Tennessee, United States.

Study timeline: The study is currently recruiting, aims to enroll about 44 participants, started in August 2020, and is expected to complete by December 2026.

Effects of Age, Sex and Isometric Exercise on Ventricular-Vascular Interactions During Cardiac Unloading (https://clinicaltrials.gov/study/NCT06939153)

Trial number: NCT06939153

Overview: This study investigates how the heart and blood vessels interact during a laboratory test that simulates low blood pressure, especially focusing on differences by age and sex, and whether handgrip exercise can help prevent blood pressure drops. Participants will lie in a chamber that creates a vacuum around their legs to mimic standing up quickly, while heart and blood pressure measurements are taken.

Who can participate: Healthy adults aged 18-35 or 65 and older without symptoms of orthostatic intolerance, with controlled blood pressure, a body mass index under 35, and who are recreationally active; both males and females can join, with additional criteria for young females regarding menstrual cycles.

Where the study is taking place: The study is being conducted at the University of Massachusetts Boston in Boston, Massachusetts, United States.

Study timeline: The study is currently recruiting, aims to enroll about 64 participants, started in May 2025, and is expected to complete primary data collection by August 2026 and full study completion by December 2026.

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure (https://clinicaltrials.gov/study/NCT02897063)

Trial number: NCT02897063

Overview: This study is investigating how two medications, midodrine and droxidopa, affect the veins in the abdomen and blood flow in patients with autonomic failure who experience low blood pressure when standing. Participants will receive these medications or placebo on separate days and undergo tests including tilt table assessments to measure blood pressure and heart function.

Who can participate: Adults aged 40 to 80 with certain neurological conditions causing autonomic failure and low blood pressure upon standing may join if they meet specific health criteria and can give informed consent; people with certain heart conditions, pregnancy, or other health issues are excluded.

Where the study is taking place: The study is conducted at the Autonomic Dysfunction Center at Vanderbilt University Medical Center in Nashville, Tennessee, United States.

Study timeline: The study is currently recruiting up to an estimated 34 participants, started in September 2016, and is expected to complete by December 2026. The total study duration for each participant is about 5 days.

Effects of Non-invasive Brain Stimulation on Pain Avoidance Behavior in Chronic Pain Patients (https://clinicaltrials.gov/study/NCT07791966)

Trial number: NCT07791966

Overview: This study is investigating whether a gentle brain stimulation method called transcranial alternating current stimulation (tACS) can change how people with chronic pain avoid activities due to pain. Participants will receive either real or fake tACS while completing tasks and having brain activity measured with special devices.

Who can participate: Adults aged 18 or older with Complex Regional Pain Syndrome (CRPS) lasting at least six months, experiencing severe daily pain, and not currently using certain neurostimulation treatments may join; people with severe psychiatric disorders or other serious health conditions are excluded.

Where the study is taking place: The study is recruiting participants at the Cleveland Clinic in Cleveland, Ohio, United States.

Study timeline: The study is currently recruiting, plans to enroll about 30 participants, and is estimated to start in October 2026 with completion expected by December 2028.

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease (https://clinicaltrials.gov/study/NCT07478172)

Trial number: NCT07478172

Overview: This study is testing a type of exercise called whole-body electrical muscle stimulation (WB-EMS) that uses electrical currents to activate muscles in adults with neuromuscular diseases who may have difficulty with traditional exercise. Participants will do supervised 20-minute WB-EMS sessions 1-2 times per week for 4-8 weeks while researchers measure muscle and nerve function, physical abilities, and symptoms like fatigue and pain.

Who can participate: Adults aged 18 or older with certain neuromuscular diseases who can stand for about 15 minutes and have some muscle strength may join; people with implanted electrical devices, unstable health conditions, or certain other medical issues are excluded.

Where the study is taking place: The study is recruiting participants at the NextGen Precision Health Building, Clinical and Translational Science Unit in Columbia, Missouri, United States.

Study timeline: The study started in March 2026 and is currently recruiting up to 50 participants; it is expected to complete primary data collection by December 2030 and finish by January 2031.

Empowered Relief for Caregivers (https://clinicaltrials.gov/study/NCT07636980)

Trial number: NCT07636980

Overview: This study is testing a single two-hour online class called Empowered Relief for Caregivers (ER-CY) that teaches skills to help caregivers manage stress and respond to their child’s chronic pain. Researchers want to see if caregivers find the program helpful and if it reduces their distress and improves their child’s daily functioning.

Who can participate: Caregivers who speak English and care for a child or teen with chronic pain lasting more than three months can join; participants must be at least 18 years old and not have severe psychological issues that prevent group participation.

Where the study is taking place: The study is conducted at Stanford University in Palo Alto, California, with the class delivered virtually via Zoom.

Study timeline: The study is not yet recruiting and plans to enroll about 80 caregivers; it is estimated to start in October 2026 and finish by September 2028, with follow-up assessments over three months after the class.

Epidural Stimulation After Neurologic Damage (https://clinicaltrials.gov/study/NCT03026816)

Trial number: NCT03026816

Overview: This study is investigating how to optimize settings for epidural spinal cord stimulation, a device placed on the spinal cord, to help people with spinal cord injuries regain voluntary leg movement and improve functions like blood pressure control and bladder function.

Who can participate: Adults aged 22 or older with stable, motor-complete paraplegia from a spinal cord injury between the C6 and T10 levels, who meet specific health and medical criteria, can participate.

Where the study is taking place: The study is being conducted at Hennepin County Medical Center in Minneapolis, Minnesota, United States.

Study timeline: The study began in August 2017 and is currently recruiting participants, aiming to enroll about 100 people, with estimated completion in January 2028.

Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies (https://clinicaltrials.gov/study/NCT07640555)

Trial number: NCT07640555

Overview: This study is testing a new imaging agent called [¹⁸F]MODAG-009 to see how it works and how safe it is for people with Parkinson’s disease, Multiple System Atrophy, and healthy adults; participants will receive one injection followed by brain imaging with a special PET scanner. 

Who can participate: Adults aged 50 to 80 with Parkinson’s disease, Multiple System Atrophy, or healthy controls who meet specific medical and imaging criteria; participants must not have other major neurological diseases or certain medical conditions. 

Where the study is taking place: The study is recruiting participants at the Institute for Neurodegenerative Disorders and XingImaging, LLC in New Haven, Connecticut, United States. 

Study timeline: The study started in May 2026 and is estimated to complete in May 2027, aiming to enroll about 13 participants and is currently recruiting.

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE) (https://clinicaltrials.gov/study/NCT07210515)

Trial number: NCT07210515

Overview: This study is testing the effects of an intravenous drug called neridronate on adults with a specific type of Complex Regional Pain Syndrome (CRPS-1) that affects one warm, swollen limb and shows certain bone scan changes. Participants will receive neridronate or a placebo through infusions on four separate days and be followed for about 12 weeks after treatment.

Who can participate: Adults aged 18 or older diagnosed with the warm subtype of CRPS-1 in one limb, with symptoms starting within the last 6 months, and who meet specific clinical and bone scan criteria can join. Women who can become pregnant must use effective birth control during and after the study.

Where the study is taking place: The study is recruiting participants at multiple Ambros Clinical Trial Sites across various U.S. cities including Phoenix, Tucson, Little Rock, La Jolla, Napa, Pasadena, Tustin, Washington D.C., Brandon, Daytona Beach, Pembroke Pines, Lawrenceville, Newnan, Orland Park, Overland Park, Reno, Shrewsbury, Charlotte, Wilmington, Winston-Salem, Dayton, Fort Worth, Houston, Lubbock, Mesquite, Charlottesville, and Seattle.

Study timeline: The study is currently recruiting and plans to enroll about 270 participants. It started in April 2026, with estimated primary completion in December 2027 and overall completion in January 2028. Each participant’s involvement lasts about 18 weeks including screening, treatment, and follow-up.

Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers (https://clinicaltrials.gov/study/NCT07617688)

Trial number: NCT07617688

Overview: This study is testing a radioactive tracer called [¹⁸F]MODAG-009 by giving a single injection to healthy adults and then taking detailed whole-body PET scans to see how the tracer spreads and behaves in the body.

Who can participate: Healthy men and women aged 18 to 60 who meet specific health and safety criteria, including birth control requirements for women, can join the study.

Where the study is taking place: The study is being conducted at the Institute for Neurodegenerative Disorders and XingImaging, LLC in New Haven, Connecticut, USA.

Study timeline: The study is currently recruiting up to 6 participants, started in May 2026, and is expected to complete by May 2027.

Examining the Circadian Timing Effects of the Hypotensive Response to Exercise (https://clinicaltrials.gov/study/NCT07049783)

Trial number: NCT07049783

Overview: This study is investigating how the timing of exercise during the day affects blood pressure in adults with elevated or high blood pressure by having participants complete treadmill exercise sessions at different biological times and measuring blood pressure before and after each session.

Who can participate: Adults aged 18 to 39 years with resting blood pressure between 120/80 mmHg and less than 140/90 mmHg, without certain health conditions, sleep disorders, high physical activity levels, or other listed exclusions.

Where the study is taking place: The study is being conducted at the University of Delaware in Newark, Delaware, United States.

Study timeline: The study is currently recruiting, plans to enroll about 30 participants, started on July 22, 2025, and is estimated to complete in September 2026.

Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome (https://clinicaltrials.gov/study/NCT07238465)

Trial number: NCT07238465

Overview: This study investigates how the sympathetic nervous system (SNS), which controls heart rate and blood pressure during stress, functions in individuals with Down syndrome by measuring heart rate, blood pressure, and stress hormones during six different stress tests.

Who can participate: Adults aged 18 to 50 who are generally healthy, including those with Down syndrome who meet specific health criteria, and who have a study partner to assist; certain health conditions and medication use exclude participation.

Where the study is taking place: The study is conducted at the Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States.

Study timeline: The study is currently recruiting, aims to enroll about 200 participants, started in April 2026, and is expected to complete primary data collection by December 2028 and full completion by December 2029.

External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia (https://clinicaltrials.gov/study/NCT07082478)

Trial number: NCT07082478

Overview: This pilot study is investigating how blood flow to the head changes in people with low blood sugar after weight-loss surgery compared to others, using a small in-ear device and a glucose monitor worn for 10 days to collect data.

Who can participate: Adults aged 18 to 70 who can consent and follow study procedures, including keeping diaries and allowing medical record review; participants must have an iPhone with iOS 16 or later and home Wi-Fi, and meet specific health criteria without certain heart, neurological, or other medical conditions.

Where the study is taking place: The study is conducted at the Joslin Diabetes Center in Boston, Massachusetts, United States, with one remote follow-up visit by phone or video.

Study timeline: The study is currently recruiting, plans to enroll about 5 participants, started on July 28, 2025, and is expected to complete by September 15, 2026; participant involvement includes three visits over about 10 days.

Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging (https://clinicaltrials.gov/study/NCT03872102)

Trial number: NCT03872102

Overview: This study is investigating brain imaging markers to help predict how quickly Parkinson’s disease progresses and to distinguish Parkinson’s disease from similar conditions like multiple system atrophy and progressive supranuclear palsy. Participants will undergo various brain scans and clinical assessments over time.

Who can participate: Adults with Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy, or healthy individuals without neurodegenerative diseases may join if they meet specific medical criteria, can attend visits for about two years, and can provide consent; certain health conditions and language requirements apply.

Where the study is taking place: The study is recruiting participants at UT Southwestern Medical Center in Dallas, Texas, United States.

Study timeline: The study began in March 2019 and is currently recruiting, aiming to enroll about 90 participants, with estimated completion by December 2026.

Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE) (https://clinicaltrials.gov/study/NCT07502599)

Trial number: NCT07502599

Overview: This study is investigating how signals from a wearable Holter monitor relate to fainting conditions called orthostatic hypotension and vasovagal syncope, aiming to understand symptom severity through monitoring and questionnaires.

Who can participate: Adults aged 18 or older who have had a specific autonomic reflex test and were diagnosed with orthostatic hypotension, vasovagal syncope, or are healthy controls; participants must be able to consent and complete study activities.

Where the study is taking place: The study is recruiting participants at the Mayo Clinic Foundation in Rochester, Minnesota, United States.

Study timeline: The study began in August 2026 and is estimated to complete in September 2028, aiming to enroll about 40 participants with one in-person visit and a 21-day monitoring period per participant.

Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial (https://clinicaltrials.gov/study/NCT07757555)

Trial number: NCT07757555

Overview: This study is testing whether the medications guanfacine or cromolyn sodium can improve symptoms and physical functioning in adults with Postural Orthostatic Tachycardia Syndrome (POTS), a condition causing rapid heart rate and other symptoms when standing. Participants will receive each medication and a placebo in separate 4-week periods while continuing usual non-drug treatments, and researchers will measure changes in symptoms and collect biological samples.

Who can participate: Adults aged 18 to 100 with a confirmed diagnosis of POTS based on heart rate and symptom criteria, who have had symptoms for at least 3 months, and who do not have other medical conditions that explain their symptoms; pregnant or breastfeeding individuals cannot participate.

Where the study is taking place: The study is conducted at Johns Hopkins Hospital in Baltimore, Maryland, United States.

Study timeline: The study is not yet recruiting and plans to enroll about 25 participants; it is estimated to start in August 2026 and complete by February 2028.

Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury (https://clinicaltrials.gov/study/NCT07674511)

Trial number: NCT07674511

Overview: This study is investigating whether transcutaneous spinal stimulation, a method of applying electrical stimulation through the skin to the spinal cord, can help control blood pressure and improve symptoms of orthostatic hypotension in people with spinal cord injury. Participants will receive stimulation during tilt-table testing and in multiple sessions while seated.

Who can participate: Adults aged 18 to 75 with a spinal cord injury at or above the T6 level for at least one year, who experience low blood pressure or orthostatic hypotension symptoms, and meet specific health criteria can join the study.

Where the study is taking place: The study is conducted at Kessler Foundation in West Orange, New Jersey, United States.

Study timeline: The study is not yet recruiting, aims to enroll about 10 participants, and is estimated to start in September 2026 with completion expected by December 2028.

Inappropriate Sinus Tachycardia Registry (https://clinicaltrials.gov/study/NCT05107635)

Trial number: NCT05107635

Overview: This study is collecting real-world data on the safety and performance of AtriCure devices used to treat Inappropriate Sinus Tachycardia (IST) or Postural Tachycardia Syndrome (POTS) by ablating heart tissue; it includes both past and ongoing cases from multiple centers.

Who can participate: Adults aged 18 to 100 who have had or are scheduled to have a procedure using AtriCure devices for IST or POTS and can provide informed consent; people in other studies affecting these conditions or with certain regulatory exclusions cannot join.

Where the study is taking place: The study is recruiting at multiple hospitals and research centers in the United States (including California, Florida, Kansas, Maryland, Ohio, Texas, Utah, Washington) and internationally in Belgium, Italy, and Poland.

Study timeline: Recruitment is currently ongoing with an estimated enrollment of 500 participants; the study began in March 2022 and is expected to complete in January 2027.

Infrared Images for Spinal Cord Stimulation in Complex Regional Pain Syndrome Patients (https://clinicaltrials.gov/study/NCT05777889)

Trial number: NCT05777889

Overview: This study is observing whether infrared thermal images can track changes in nerve-related activity caused by spinal cord stimulation in patients with complex regional pain syndrome (CRPS) affecting one leg, and how these changes relate to pain and symptom scores. Participants will have thermal images taken of their feet and complete questionnaires about their pain and symptoms.

Who can participate: Adults aged 18 to 85 with CRPS in one lower leg, experiencing pain for more than 3 months that has not improved with usual treatments, and with significant pain levels; people with certain other medical conditions or infections are excluded.

Where the study is taking place: The study is recruiting participants at the Hospital for Special Surgery in New York, New York, United States.

Study timeline: The study began in February 2023 and is estimated to complete in February 2027, currently recruiting with an estimated enrollment of 12 participants.

Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy (https://clinicaltrials.gov/study/NCT04909138)

Trial number: NCT04909138

Overview: This study is testing two different intermittent dosing patterns of dorsal root ganglion (DRG) stimulation, a type of nerve stimulation used to manage chronic pain, to see if cycling the stimulation on and off at different frequencies helps maintain or improve pain relief compared to continuous stimulation.

Who can participate: Adults aged 18 to 90 who have had a permanent DRG stimulator implanted for at least one year, have experienced at least 50% pain relief with continuous stimulation, and meet other health and treatment stability criteria can join.

Where the study is taking place: The study is recruiting participants at Rush University Medical Center in Chicago, Illinois, United States.

Study timeline: The study began in October 2022 and is currently recruiting, aiming to enroll about 30 participants, with estimated completion in June 2027; participants will be followed and evaluated at multiple points over about 25 weeks during the study.

International Rapid-onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation (ROHHAD) Registry (https://clinicaltrials.gov/study/NCT03135730)

Trial number: NCT03135730

Overview: This study is creating an international registry to collect detailed health information from patients with ROHHAD, a rare disorder causing rapid weight gain and problems with breathing, hormone control, and the nervous system, to better understand the disease and improve care guidelines.

Who can participate: People of any age and sex with a clinical diagnosis of suspected or confirmed ROHHAD can join; those without a ROHHAD diagnosis are excluded.

Where the study is taking place: The study is recruiting participants at Ann & Robert H. Lurie Children’s Hospital of Chicago in Illinois, USA.

Study timeline: The study began in June 2013 and is currently recruiting, aiming to enroll about 1000 participants, with estimated completion in December 2039.

Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis (https://clinicaltrials.gov/study/NCT05989763)

Trial number: NCT05989763

Overview: This study is investigating whether a treatment called transcutaneous electrical acustimulation (TEA), which uses mild electrical stimulation on the skin, can improve bowel function and nerve activity in people with systemic sclerosis who have constipation. Researchers want to see if TEA affects how the colon moves and how sensitive the rectum is, as well as its impact on nerve function and inflammation.

Who can participate: Adults aged 18 and older with systemic sclerosis who have constipation related to slow colon movement or reduced rectal sensitivity, and who are either not yet treated or have stable treatment for constipation, may be eligible. People with mixed diarrhea and constipation symptoms are excluded.

Where the study is taking place: The study is being conducted at The University of Texas Health Science Center at Houston in Houston, Texas, United States.

Study timeline: The study began in February 2024 and is currently recruiting participants, aiming to enroll about 60 people. The estimated primary completion date is August 2028, with overall study completion expected by September 2029.

LIFT: Life Improvement Trial (https://clinicaltrials.gov/study/NCT06366724)

Trial number: NCT06366724

Overview: This study is testing the effects of two drugs, Pyridostigmine and Low-Dose Naltrexone, on adults with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Orthostatic Intolerance, including those with Long COVID; participants will receive one of four treatment combinations or placebos and undergo exercise tests, questionnaires, and lab tests over about three months. 

Who can participate: Adults aged 18 to 70 who meet specific ME/CFS criteria with Orthostatic Intolerance, are not pregnant, have a body mass index between 17 and 40, and meet other health and medication use requirements; participants must also have a smartphone for study app use. 

Where the study is taking place: Brigham and Women’s Hospital in Boston, Massachusetts, United States. 

Study timeline: The study is currently recruiting, plans to enroll about 160 participants, started in September 2024, and is expected to complete by November 2026; individual participation lasts about three months.

Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome (https://clinicaltrials.gov/study/NCT02502162)

Trial number: NCT02502162

Overview: This study is testing whether low-dose naltrexone (LDN) can help relieve symptoms of complex regional pain syndrome (CRPS). Participants will be randomly assigned to receive either LDN or a placebo (a sugar pill) and will attend in-person or virtual visits while completing questionnaires.

Who can participate: Adults aged 18 to 70 with CRPS in an arm or leg for at least one year, who meet specific diagnostic criteria and have been on stable treatment for at least one month, may join; people allergic to naltrexone, using opioids, or pregnant are excluded.

Where the study is taking place: The study is recruiting participants at Stanford University in Palo Alto, California, United States.

Study timeline: The study began in June 2015 and is currently recruiting, aiming to enroll about 120 participants; it is expected to complete in July 2027.

Mild Intermittent Hypoxia: A Prophylactic for Autonomic Dysfunction in Individuals With Spinal Cord Injuries (https://clinicaltrials.gov/study/NCT05351827)

Trial number: NCT05351827

Overview: This study is investigating whether mild intermittent hypoxia (brief periods of low oxygen) combined with nightly use of a breathing device (CPAP) can help prevent problems with blood pressure control and improve related functions in people with spinal cord injuries and sleep breathing issues.

Who can participate: Adults aged 18 to 60 with incomplete spinal cord injuries at or above the 12th thoracic vertebra, showing signs of autonomic dysfunction, and who are more than one year post-injury may join; certain conditions like pregnancy, smoking, complete spinal cord injury, and others exclude participation.

Where the study is taking place: The study is recruiting participants at the John D. Dingell VA Medical Center in Detroit, Michigan, United States.

Study timeline: The study began in October 2022 and is currently recruiting, aiming to enroll about 24 participants, with estimated completion in October 2027.

Modifiable Variables in Parkinsonism (MVP) (https://clinicaltrials.gov/study/NCT02194816)

Trial number: NCT02194816

Overview: This study is observing people with Parkinson’s disease and related conditions to learn about factors linked to better quality of life and fewer symptoms by collecting information through surveys about health, diet, and lifestyle every six months for five years.

Who can participate: Adults aged 19 and older with Parkinson’s disease, Parkinsonism, or related syndromes who have internet access, an email address, and basic computer skills, and who are willing to complete online surveys every six months.

Where the study is taking place: The study is recruiting participants at Bastyr University in Kenmore, Washington, United States.

Study timeline: The study began in September 2012 and is estimated to complete in December 2030, aiming to enroll about 2,000 participants; recruitment is currently ongoing.

Multiple System Atrophy Multidisciplinary Clinic (https://clinicaltrials.gov/study/NCT03811808)

Trial number: NCT03811808

Overview: This study is investigating the effects of multidisciplinary care on people with multiple system atrophy (MSA) and their caregivers by collecting information through questionnaires and rating scales completed at home or during clinic visits. 

Who can participate: Adults aged 18 or older with possible or probable MSA who are patients at the UT Southwestern MSA clinic, able to attend visits every four months, and able to give consent; non-English speakers and those diagnosed with dementia cannot participate. 

Where the study is taking place: The study is conducted at the UT Southwestern Medical Center in Dallas, Texas, United States. 

Study timeline: The study is currently recruiting, aims to enroll about 200 participants, started in March 2016, and is estimated to complete in March 2028.

Natural History Study of Synucleinopathies (https://clinicaltrials.gov/study/NCT01799915)

Trial number: NCT01799915

Overview: This study is observing people with synucleinopathies, a group of rare diseases that affect the nervous system and cause movement, coordination, or thinking problems, to understand how these diseases develop and find biological signs that predict disease progression.

Who can participate: Adults aged 18 or older who have symptoms of dizziness or lightheadedness when standing, without certain other health conditions like diabetes or heart failure, and who can attend follow-up visits at study centers.

Where the study is taking place: The study is recruiting participants at multiple locations including Boston, Ann Arbor, Rochester, New York, Nashville, Buenos Aires, Seoul, and Bilbao.

Study timeline: The study began in June 2011, is currently recruiting, aims to enroll about 800 participants, and expects to complete by December 2026.

Neurologic Stem Cell Treatment Study (https://clinicaltrials.gov/study/NCT02795052)

Trial number: NCT02795052

Overview: This study is testing whether stem cells taken from a patient’s own bone marrow and given through the bloodstream and inside the lower part of the nose can improve nerve function in people with certain neurological conditions.

Who can participate: Adults over 18 with lasting nerve damage from neurological diseases or injuries, stable on current treatments, medically cleared for the procedure, and able to consent can join; pregnant women or those at high medical risk are excluded.

Where the study is taking place: The study is recruiting participants at MD Stem Cells locations in Westport, Connecticut; Coral Springs, Florida; and at The Saudi-German Hospital in Dubai, United Arab Emirates.

Study timeline: The study began in June 2016, is currently recruiting, aims to enroll about 500 participants, and expects to complete primary data collection by July 2027 and the entire study by July 2028.

NightWare and Cardiovascular Health in Veterans With PTSD (https://clinicaltrials.gov/study/NCT06419959)

Trial number: NCT06419959

Overview: This study is testing a wrist-worn device called NightWare that aims to reduce nightmares and improve sleep in Veterans with PTSD, and it will also look at whether using the device affects heart health. Participants will wear the device for 8 weeks to see if it helps with sleep quality and cardiovascular measures.

Who can participate: Veterans aged 22 to 88 years with PTSD and frequent nightmares that disrupt sleep may join if they meet health and safety criteria, including stable blood pressure and no serious medical or psychiatric conditions that would interfere with the study.

Where the study is taking place: The study is being conducted at the Rocky Mountain Regional VA Medical Center in Aurora, Colorado.

Study timeline: The study is currently recruiting and plans to enroll about 125 participants; it started in September 2025 and is expected to complete by December 2026.

NightWare and Cardiovascular Health in Women With PTSD (https://clinicaltrials.gov/study/NCT07021014)

Trial number: NCT07021014

Overview: This study is investigating whether NightWare, a smartwatch app that disrupts nightmares, can improve blood vessel and kidney function in premenopausal women with PTSD-related nightmares, comparing results to women without PTSD.

Who can participate: Women aged 22 to 40 who are healthy, with or without PTSD and nightmares, and who meet specific medical and sleep-related criteria can join; participants must have internet access and power outlets near their sleeping area.

Where the study is taking place: The study is conducted at the University of Colorado Anschutz Medical Campus in Aurora, Colorado, and the University of Colorado CCTSI CTRC in Denver, Colorado.

Study timeline: Recruitment has not yet started; the study plans to enroll about 36 participants, with estimated dates from July 2025 to July 2028.

Non-invasive Spinal Cord Stimulation and Blood Pressure Regulation After Spinal Cord Injury (https://clinicaltrials.gov/study/NCT07504055)

Trial number: NCT07504055

Overview: This study is investigating whether non-invasive spinal cord stimulation can improve blood pressure regulation in people with chronic spinal cord injury by stimulating different spinal cord sites and measuring effects on blood pressure and related enzymes.

Who can participate: Adults aged 18 or older with stable, motor-complete spinal cord injury at or above the T1 level for at least one year, who have symptoms of low blood pressure and meet specific health criteria, can participate.

Where the study is taking place: The study is being conducted at the Frazier Rehabilitation and Neuroscience Institute and Frazier Rehabilitation Institute in Louisville, Kentucky, United States.

Study timeline: The study is currently recruiting up to 40 participants, started in April 2026, and is expected to complete in February 2029, with participants undergoing up to 80 stimulation sessions over 16 to 20 weeks.

Noninvasive CA Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage (https://clinicaltrials.gov/study/NCT07577739)

Trial number: NCT07577739

Overview: This study investigates brain blood flow regulation in adults with aneurysmal subarachnoid hemorrhage (aSAH) using a noninvasive device compared to standard invasive monitoring, and tests two nerve-related treatments to see their effects on this regulation. Researchers aim to better understand and potentially improve brain blood flow control during a critical period after hemorrhage.

Who can participate: Adults aged 18 or older diagnosed with aSAH and admitted to the Neurosciences Intensive Care Unit at UT Southwestern Medical Center, who meet specific medical and consent criteria; additional requirements apply for the nerve treatment part of the study.

Where the study is taking place: UT Southwestern Medical Center – Clements University Hospital Neurosciences Intensive Care Unit in Dallas, Texas, United States.

Study timeline: The study is not yet recruiting, with an estimated start date in July 2026, aiming to enroll about 300 participants, and estimated completion by June 2030.

NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease (https://clinicaltrials.gov/study/NCT07398508)

Trial number: NCT07398508

Overview: This study is testing the drug Northera (Droxidopa) in children with Menkes disease who have symptoms of dysautonomia, such as dizziness and low blood pressure, to see if the drug is safe and can improve symptoms and quality of life. Participants will receive either Droxidopa or a placebo in a controlled trial and undergo tests to measure blood pressure, neurochemical levels, and physical performance.

Who can participate: Children and adolescents aged 7 to 17 years with Menkes disease who have survived early treatment and show symptoms of dysautonomia, can take oral medication, and meet specific health criteria; both parent consent and patient assent are required.

Where the study is taking place: The study is recruiting participants at Vagelos College of Physicians and Surgeons, Columbia University, in New York, New York, United States.

Study timeline: The study is currently recruiting with an estimated enrollment of 6 participants; it is expected to start in August 2026 and complete by June 2030.

NYSCF Scientific Discovery Biobank (https://clinicaltrials.gov/study/NCT06203106)

Trial number: NCT06203106

Overview: This study collects skin, blood, and saliva samples to create stem cells and perform genetic testing, aiming to support research on many diseases and traits for future discoveries. Participants complete health questionnaires and may be contacted later for more information or studies.

Who can participate: People aged 30 days or older with certain diseases, genetic backgrounds, or traits of interest, as well as healthy controls, can join; consent or assent with guardian permission is required depending on age and decision-making ability.

Where the study is taking place: The study is conducted at the New York Stem Cell Foundation Research Institute in New York, New York, United States.

Study timeline: The study began in November 2022, is currently recruiting, plans to enroll about 10,000 participants, and is expected to complete by November 2045.

Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension (https://clinicaltrials.gov/study/NCT03042988)

Trial number: NCT03042988

Overview: This study is investigating whether applying local heat to the abdomen during the night can lower high blood pressure that occurs while lying down in patients with autonomic failure, a condition affecting blood pressure regulation. Participants will receive either heat treatment or a non-heated control to compare effects on nighttime blood pressure.

Who can participate: Adults aged 18 to 80 with primary autonomic failure and high blood pressure when lying down (supine hypertension) may join if they can give informed consent; people who are pregnant or have serious heart, kidney, or liver problems are excluded.

Where the study is taking place: The study is being conducted at the Autonomic Dysfunction Center at Vanderbilt University Medical Center in Nashville, Tennessee, United States.

Study timeline: The study began in January 2017 and is currently recruiting participants, aiming to enroll about 20 people, with estimated completion by December 2026.

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE) (https://clinicaltrials.gov/study/NCT04752293)

Trial number: NCT04752293

Overview: This study is investigating how certain substances in the body, including parts of the renin-angiotensin-aldosterone system, uric acid, and klotho, may contribute to high blood pressure and related damage to the heart, kidneys, blood vessels, and brain in children. Participants will have blood and urine samples taken and undergo tests of blood pressure and organ function over two years.

Who can participate: Children and adolescents aged 7 to 18 years with newly diagnosed primary hypertension or healthy children with normal blood pressure can join, provided they and their caregivers can complete study assessments; certain medical conditions, pregnancy, and language barriers exclude participation.

Where the study is taking place: The study is recruiting participants at Wake Forest Health Sciences in Winston-Salem, North Carolina, United States.

Study timeline: The study began in May 2021 and is currently recruiting, aiming to enroll about 125 participants, with estimated completion in December 2026.

Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities? (https://clinicaltrials.gov/study/NCT05618054)

Trial number: NCT05618054

Overview: This study is investigating how people with Postural Tachycardia Syndrome (POTS), a condition affecting heart rate and blood flow, perceive images while their brain activity is scanned using fMRI; participants will press a button when they see images to help researchers understand brain communication in POTS.

Who can participate: Females aged 12 to 21 who speak English and either have a POTS diagnosis or are healthy without neurological disorders can join; certain health conditions and recent medical treatments exclude participation.

Where the study is taking place: The study is being conducted at Virginia Commonwealth University in Richmond, Virginia, United States.

Study timeline: The study began in March 2023 and is currently recruiting participants, aiming to enroll about 36 individuals, with estimated completion in December 2026.

Personalized Brain Stimulation to Treat Chronic Concussive Symptoms (https://clinicaltrials.gov/study/NCT06073886)

Trial number: NCT06073886

Overview: This study is testing a personalized, noninvasive brain stimulation treatment called transcranial magnetic stimulation (TMS) to see if it can improve brain function and reduce chronic symptoms after concussion, such as dizziness, headache, fatigue, and memory problems. Participants will receive either active or inactive TMS and undergo brain scans and symptom assessments.

Who can participate: Adults aged 18 to 65 who have had a mild traumatic brain injury (concussion) within the past 12 months and have significant ongoing symptoms, without certain medical conditions or contraindications for TMS or MRI, and who can speak and read English.

Where the study is taking place: The study is being conducted at the University of California Los Angeles (UCLA) in Westwood, Los Angeles, California, United States.

Study timeline: The study is currently recruiting and plans to enroll about 75 participants; it started in March 2024, with estimated primary completion in July 2026 and overall completion in January 2027.

PET Imaging Evaluation of [11C]SY08 (https://clinicaltrials.gov/study/NCT06098612)

Trial number: NCT06098612

Overview: This study is testing a new PET imaging agent called [11C]SY08 to see how it behaves in the brain and to detect protein clumps called alpha synuclein in people with Parkinson’s disease, Multiple System Atrophy, Dementia with Lewy Bodies, and healthy individuals. Participants will receive an injection of [11C]SY08 and undergo brain PET scans.

Who can participate: Adults aged 50 to 80 who speak English and can consent are eligible, including those diagnosed with Parkinson’s disease, Multiple System Atrophy, or Dementia with Lewy Bodies, as well as healthy volunteers; participants must meet specific health and safety criteria and have a study partner for certain groups.

Where the study is taking place: The study is recruiting participants at Massachusetts General Hospital in Charlestown, Massachusetts, United States.

Study timeline: Recruitment is ongoing with an estimated enrollment of 40 participants; the study started in May 2024 and is expected to complete primary data collection by November 2026 and overall completion by November 2027.

Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS) (https://clinicaltrials.gov/study/NCT06292104)

Trial number: NCT06292104

Overview: This study aims to better understand Postural Orthostatic Tachycardia Syndrome (POTS) by using various tests like blood work, skin biopsy, and heart and blood volume measurements to identify different types of POTS and improve diagnosis and treatment options.

Who can participate: People aged 14 and older with POTS who meet specific heart rate and symptom criteria, as well as healthy women aged 18 to 30 without POTS or related symptoms, can join the study.

Where the study is taking place: The study is being conducted at UT Southwestern Medical Center in Dallas, Texas, United States.

Study timeline: The study started in March 2024 and is currently recruiting participants, aiming to enroll about 350 people, with estimated completion in January 2029.

Potential Benefits of Parent Child Interaction Therapy (PCIT) (https://clinicaltrials.gov/study/NCT06827951)

Trial number: NCT06827951

Overview: This study is investigating the possible benefits of Parent-Child Interaction Therapy (PCIT) on parental stress, parent-child attachment, and biological stress markers by having parents complete the PCIT program and several online surveys before, during, and after the therapy.

Who can participate: Parents aged 18 to 89 who are the primary caregivers of children aged 2 to 7 with behavioral concerns and who have not previously done PCIT; participants must be fluent in English and able to attend all sessions.

Where the study is taking place: The study is recruiting participants at UF Health Child Psychiatry in Gainesville, Florida, and UF Health Psychiatry San Jose in Jacksonville, Florida.

Study timeline: Recruitment is ongoing with an estimated enrollment of 80 participants; the study started on February 14, 2025, and is expected to complete by June 1, 2026.

Presentation of Young Adults With and Without Joint Hypermobility (https://clinicaltrials.gov/study/NCT07657507)

Trial number: NCT07657507

Overview: This study is investigating why some people with flexible joints (called Generalized Joint Hypermobility or GJH) have no symptoms, while others develop health problems known as Hypermobile Ehlers-Danlos Syndrome (hEDS) or Hypermobility Spectrum Disorder (HSD). Participants will complete questionnaires about their health and undergo physical tests of joint flexibility, balance, neck control, and heart rate response to standing.

Who can participate: The study is open to healthy students aged 18 to 60 years enrolled in the Health Sciences program at Clarkson University, without physical conditions that prevent most physical tests.

Where the study is taking place: The study is conducted at Clarkson University, Lewis School of Health & Life Sciences, in Potsdam, New York, United States.

Study timeline: The study is not yet recruiting and plans to enroll about 100 participants starting around June 2026, with follow-up continuing for about 10 years until June 2036.

Prospective Case Series Evaluating 6-Month and 12-Month Outcomes After Cryoneurolysis for Chronic Pain (https://clinicaltrials.gov/study/NCT07639060)

Trial number: NCT07639060

Overview: This study is observing outcomes for up to 12 months after patients receive cryoneurolysis, a procedure used as routine care to treat chronic pain in specific body areas. Researchers want to understand patient experiences and healthcare use following the treatment.

Who can participate: Adults aged 18 and older with chronic pain lasting at least 3 to 6 months in a body area suitable for cryoneurolysis, who are planning to have the procedure and can complete questionnaires, may join. People with certain health issues or in other conflicting studies are excluded.

Where the study is taking place: The study is recruiting participants at Yale New Haven Health Old Saybrook Medical Center in Old Saybrook, Connecticut, United States.

Study timeline: The study began on June 20, 2026, is currently recruiting, aims to enroll about 80 participants, and expects to complete primary data collection and the study by July 2028.

Rare Disease Patient Registry & Natural History Study – Coordination of Rare Diseases at Sanford (https://clinicaltrials.gov/study/NCT01793168)

Trial number: NCT01793168

Overview: This study collects and stores information from people with rare diseases or undiagnosed conditions to create a large patient registry that helps researchers connect and advance rare disease research.

Who can participate: People of any age and sex who have a rare disease, an undiagnosed condition, or are carriers of rare diseases can join; those with common diseases cannot participate.

Where the study is taking place: Participants can enroll through Sanford Health in Sioux Falls, South Dakota, USA, or via an online enrollment system based in Sydney, Australia.

Study timeline: The study began in July 2010 and is currently recruiting, aiming to enroll about 20,000 participants; the estimated completion date is December 2100.

Remote Monitoring in Progressive Supranuclear Palsy (PSP) (https://clinicaltrials.gov/study/NCT04753320)

Trial number: NCT04753320

Overview: This study is observing how wearable sensors and digital tools can track falls, movement, speech, and thinking skills in people with progressive supranuclear palsy (PSP) over about one year, with monthly remote check-ins and in-person visits every six months. 

Who can participate: Adults aged 18 to 89 with possible or probable PSP, Parkinson’s disease, multiple system atrophy, or healthy controls who can walk 10 feet without help, speak English, and have a caregiver to assist with study tasks. 

Where the study is taking place: The study is conducted at Johns Hopkins in Baltimore, Maryland, and Massachusetts General Hospital in Boston, Massachusetts, United States. 

Study timeline: The study is not yet recruiting, plans to enroll about 85 participants, and is estimated to start in September 2026 with completion expected by December 2028.

Restoring Iron Deficiency in POTS (https://clinicaltrials.gov/study/NCT07197905)

Trial number: NCT07197905

Overview: This study is investigating whether giving intravenous iron to people with postural orthostatic tachycardia syndrome (POTS) who have low iron storage (low ferritin) can increase their red blood cell volume and improve their symptoms. Participants will have medical exams, blood tests, autonomic function tests, and wear an activity monitor before and two months after iron treatment.

Who can participate: Women aged 18 to 45 years with a POTS diagnosis, low ferritin levels (below 50 ng/ml), and no other conditions causing their symptoms may join. Participants must not be pregnant, bedridden, or have recent iron treatment or bleeding issues, and must be able to hold certain medications during testing.

Where the study is taking place: The study is being conducted at the Autonomic Dysfunction Center at Vanderbilt University Medical Center in Nashville, Tennessee, United States.

Study timeline: The study is currently recruiting and plans to enroll about 12 participants. It started on November 24, 2025, with estimated primary completion in October 2026 and overall completion by December 2026.

Role of the Gut Microbiome in Complex Regional Pain Syndrome (https://clinicaltrials.gov/study/NCT03612193)

Trial number: NCT03612193

Overview: This study is investigating how the types of bacteria in the gut (gut microbiome) relate to the severity and persistence of Complex Regional Pain Syndrome (CRPS) symptoms and whether gut bacteria can help predict recovery in newly diagnosed patients; it also looks at thinking flexibility in relation to outcomes.

Who can participate: Adults 18 or older with a current or past diagnosis of CRPS or their cohabiting partners who speak English and can consent; certain conditions like pregnancy, vegan diet, living alone, or current probiotic use may exclude participation.

Where the study is taking place: The study is recruiting participants at Washington University School of Medicine in St. Louis, Missouri, United States.

Study timeline: The study began in December 2018, is currently recruiting, aims to enroll about 140 participants, and expects to complete by July 2027.

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations (https://clinicaltrials.gov/study/NCT07143669)

Trial number: NCT07143669

Overview: This study is screening people suspected of having a clonal mast cell disease to find out how common a specific genetic mutation called KIT D816V is in these groups. Participants will provide medical history and samples for testing.

Who can participate: Adults 18 years or older with certain conditions related to mast cell disease, anaphylaxis, or related disorders, divided into four specific groups based on their medical history and diagnoses; people with some other mast cell or blood disorders are excluded.

Where the study is taking place: The study is recruiting at multiple clinical research centers across the United States, including locations in Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland, Minnesota, Missouri, Nebraska, New York, North Carolina, Oklahoma, Pennsylvania, Rhode Island, South Carolina, and Texas.

Study timeline: The study began on October 17, 2025, is currently recruiting, aims to enroll about 750 participants, and expects to complete primary data collection by July 31, 2028, with overall study completion by October 31, 2028.

Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI) (https://clinicaltrials.gov/study/NCT05731986)

Trial number: NCT05731986

Overview: This study is investigating whether transcutaneous spinal cord stimulation can help increase and stabilize blood pressure in people with a recent spinal cord injury, especially to reduce symptoms like dizziness during position changes. Participants will undergo tests involving changes in body position with and without spinal stimulation to compare effects on blood pressure.

Who can participate: Adults aged 18 to 75 with a spinal cord injury at or above the T2 level that occurred 7 to 30 days before joining, who experience low blood pressure or related symptoms when sitting up, and who meet other health criteria listed by the study.

Where the study is taking place: The study is being conducted at Kessler Foundation in West Orange, New Jersey, United States.

Study timeline: The study began in December 2023 and is currently recruiting participants, aiming to enroll about 12 people, with estimated completion in August 2026. The record does not specify how long each participant will be involved.

Splanchnic Venous Capacitance in Postural Tachycardia Syndrome (https://clinicaltrials.gov/study/NCT05375968)

Trial number: NCT05375968

Overview: This study is investigating how blood volume changes in the abdomen (splanchnic venous capacitance) affect symptoms in people with Postural Tachycardia Syndrome (POTS) after eating glucose. Participants will undergo tests including glucose intake, blood flow measurements, and infusions to understand these effects during lying down and standing positions.

Who can participate: Adults aged 18 to 50 years with a body mass index (BMI) between 18.5 and 29.9; includes people diagnosed with POTS who have symptoms after meals and healthy individuals without major health issues. Certain health conditions and medications exclude participation.

Where the study is taking place: Vanderbilt University Medical Center in Nashville, Tennessee, United States.

Study timeline: The study is currently recruiting and plans to enroll about 50 participants; it started in February 2023 with estimated completion in June 2028.

Supraspinal Processing of Sensory Aspects of Pain (https://clinicaltrials.gov/study/NCT05814497)

Trial number: NCT05814497

Overview: This study investigates how the brain processes different types of chronic pain in children by using brain scans (fMRI), sensory tests, and psychological assessments to understand pain mechanisms and factors related to recovery and pain spread.

Who can participate: Children and teenagers aged 10 to 17 with specific chronic pain conditions such as migraine, complex regional pain syndrome, functional abdominal pain, or musculoskeletal pain, who meet certain health and medication stability criteria, as well as healthy volunteers.

Where the study is taking place: The study is being conducted at Cincinnati Children’s Hospital in Cincinnati, Ohio, United States.

Study timeline: The study began in May 2023 and is currently recruiting participants, aiming to enroll about 255 people, with estimated completion in June 2027.

The CurePSP Genetics Program (https://clinicaltrials.gov/study/NCT06647641)

Trial number: NCT06647641

Overview: This study is observing genetic information by collecting and analyzing DNA from adults diagnosed with PSP, CBS, MSA, or related neurological conditions and their families to better understand these diseases and support future research and counseling. Participants will provide blood samples for whole genome sequencing at the National Institutes of Health.

Who can participate: Adults aged 35 or older diagnosed with PSP, CBS, MSA, or related neurological diseases, or unaffected family members with a relevant family history, who can consent and complete study activities; certain medical conditions and recent blood transfusions exclude participation.

Where the study is taking place: The study is recruiting participants at Massachusetts General Hospital in Boston, Massachusetts, United States.

Study timeline: Recruitment is currently open with an estimated enrollment of 1,000 participants; the study started in October 2024 and is expected to complete by December 2030.

The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI) (https://clinicaltrials.gov/study/NCT05725499)

Trial number: NCT05725499

Overview: This study is investigating how electrical stimulation applied through the skin on the spinal cord affects blood pressure in people with chronic spinal cord injury who experience drops in blood pressure when moving upright (orthostatic hypotension). Participants will undergo tests where their body is tilted while receiving stimulation to see if blood pressure can be stabilized.

Who can participate: Adults aged 18 to 75 with a spinal cord injury at or above the T6 level for at least 6 months who have symptoms of low blood pressure when changing position may join; people with certain health conditions or implanted devices are excluded.

Where the study is taking place: The study is being conducted at Kessler Foundation in West Orange, New Jersey, United States.

Study timeline: The study began in February 2023 and is currently recruiting participants, aiming to enroll about 5 people, with estimated completion in August 2026.

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome (https://clinicaltrials.gov/study/NCT06393101)

Trial number: NCT06393101

Overview: This study is investigating how a cannabis extract called BRC-002, which contains cannabidiol (CBD), might affect pain and related symptoms in people with Complex Regional Pain Syndrome (CRPS). Participants will undergo tests before, during, and after treatment to understand how the extract may influence pain and other health factors.

Who can participate: Adults aged 21 to 75 with a confirmed diagnosis of CRPS for at least three months, who have not used cannabis or CBD for at least 30 days, and who do not have certain medical or psychiatric conditions may be eligible.

Where the study is taking place: The study is recruiting participants at two locations in California, United States: Altman Clinical and Translational Research Institute in La Jolla and the University of California, San Diego in San Diego.

Study timeline: The study is currently recruiting and plans to enroll about 52 participants. It is estimated to start in June 2024 and complete by June 2029, including a six-week treatment period and a two-week follow-up for each participant.

The Impact of Improved Vagal Function on Periaqueductal Gray Connectivity (https://clinicaltrials.gov/study/NCT05618067)

Trial number: NCT05618067

Overview: This study is investigating whether training and practicing specific breathing exercises can help people with Postural Tachycardia Syndrome (POTS) by improving communication between certain brain areas. Participants will be trained weekly for four weeks and will practice breathing exercises at home twice daily using an app and a heart-monitoring device.

Who can participate: Adults aged 18 to 50 who have POTS or related conditions like orthostatic intolerance or syncope, can read and speak English, and have a scheduled new patient visit at the VCU Comprehensive Autonomics Center may join; certain medical conditions and recent treatments exclude participation.

Where the study is taking place: The study is conducted at Virginia Commonwealth University in Richmond, Virginia, United States.

Study timeline: The study is not yet recruiting, aims to enroll about 12 participants, and is estimated to start in January 2028 with completion expected by December 2028.

The Long COVID-19 Wearable Device Study (https://clinicaltrials.gov/study/NCT05741112)

Trial number: NCT05741112

Overview: This study is investigating Long COVID-19 by collecting data from people who either already own wearable devices or are given one, along with educational materials, to see if these tools help manage symptoms and reduce worsening after physical activity. Participants will share wearable data and complete surveys about their symptoms and quality of life.

Who can participate: Adults 18 years or older with a diagnosis or self-diagnosis of Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), or postural orthostatic tachycardia syndrome (POTS) who are interested in symptom management tools and can use a wearable device and smartphone or tablet.

Where the study is taking place: The study is recruiting participants at Scripps Research in La Jolla, California, United States.

Study timeline: Recruitment is ongoing with an estimated enrollment of 100,500 participants; the study started on November 16, 2023, and is expected to complete by December 1, 2025.

The Natural History of Familial Dysautonomia (https://clinicaltrials.gov/study/NCT03920774)

Trial number: NCT03920774

Overview: This study observes patients with familial dysautonomia (FD) to collect clinical information and optional blood samples, aiming to understand the disease’s features, progression, and develop ways to measure neurological changes for future treatments.

Who can participate: Patients of any age with a confirmed FD diagnosis who can give consent or assent and follow the study procedures; people who do not wish to participate are excluded.

Where the study is taking place: The study is recruiting at the Dysautonomia Center at NYU Langone Medical Center in New York, USA, and at Sheba Medical Center – Safra Children’s Hospital in Ramat Gan, Israel.

Study timeline: The study began in February 2017, is currently recruiting, aims to enroll about 400 participants, and expects to complete primary data collection by February 2027 and the entire study by December 2028.

The STAND-UP Study (https://clinicaltrials.gov/study/NCT07195903)

Trial number: NCT07195903

Overview: This study is investigating a minimally invasive procedure to open narrowed veins above the heart in adults with orthostatic hypotension or intolerance, aiming to improve blood pressure control and reduce symptoms like dizziness and fainting. Participants will have imaging tests and may receive vein widening treatments using a balloon or stent, followed by regular check-ups over two years.

Who can participate: Adults aged 18 and older diagnosed with orthostatic hypotension or intolerance that has not improved with standard treatments or is complicated by high blood pressure when lying down; participants must be able to consent and not be pregnant, breastfeeding, infected, or unable to take blood thinners.

Where the study is taking place: The study is recruiting participants at St. Francis Hospital The Heart Center in Roslyn, New York, United States.

Study timeline: The study is currently recruiting, plans to enroll about 100 participants, started on January 23, 2025, and is estimated to complete by January 1, 2030, with primary results expected by January 1, 2029.

TMS for Complex Regional Pain Syndrome (https://clinicaltrials.gov/study/NCT03137472)

Trial number: NCT03137472

Overview: This study is testing whether Transcranial Magnetic Stimulation (TMS), a non-invasive brain stimulation technique, can reduce pain and other symptoms in people with Complex Regional Pain Syndrome (CRPS). Participants will receive either real or sham TMS treatment once daily for two days and will be monitored to see how long symptom relief lasts.

Who can participate: Adults aged 18 to 70 who have had CRPS for at least three months and meet certain pain level criteria may join. People with certain medical conditions, implants, pregnancy, or legal claims related to their condition are excluded.

Where the study is taking place: The study is being conducted at the Stanford Pain Management Center in Redwood City, California, United States.

Study timeline: The study began in April 2017 and is currently recruiting participants, aiming to enroll about 40 people. The estimated completion date is June 29, 2028.

Treatment of Supine Hypertension in Autonomic Failure (CPAP) (https://clinicaltrials.gov/study/NCT03312556)

Trial number: NCT03312556

Overview: This study is investigating whether continuous positive airway pressure (CPAP), a treatment that uses mild air pressure through a mask to keep airways open, can lower high blood pressure when lying down in patients with autonomic failure and supine hypertension.

Who can participate: Adults aged 18 to 85 with autonomic failure and supine hypertension may join, except pregnant women, medical students, high-risk patients with certain heart or liver conditions, and those with serious allergies or asthma.

Where the study is taking place: The study is being conducted at the Autonomic Dysfunction Center at Vanderbilt University Medical Center in Nashville, Tennessee, United States.

Study timeline: The study began in September 2017 and is currently recruiting, with an estimated enrollment of 12 participants and an expected completion date in December 2026.

Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome (https://clinicaltrials.gov/study/NCT06953661)

Trial number: NCT06953661

Overview: This study is testing whether a procedure called stellate ganglion block (SGB), which involves injecting a local anesthetic near nerves in the neck, can help control symptoms of Postural Tachycardia Syndrome (POTS), a condition causing rapid heartbeat and other symptoms when standing. Participants will receive either the SGB treatment or a sham saline injection to compare effects.

Who can participate: Adults over 18 years old diagnosed with POTS who can speak English, provide consent, and attend three follow-up visits may join; people with allergies to local anesthetics, certain heart or lung conditions, or unstable medication use are excluded.

Where the study is taking place: The study is conducted at Stanford University School of Medicine in Stanford, California, United States.

Study timeline: The study is not yet recruiting and plans to enroll about 20 participants; it is estimated to start in October 2025 and complete by November 2026.

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research (https://clinicaltrials.gov/study/NCT04806620)

Trial number: NCT04806620

Overview: This study collects health, lifestyle, and symptom data over time from people with brain inflammation and related conditions, as well as healthy individuals, using a secure app to help researchers understand these illnesses better and support future research.

Who can participate: People aged 2 years and older living in the U.S., including those with various neuroinflammatory, autoimmune, gastrointestinal, and behavioral conditions, as well as healthy individuals, who have internet access and can use the app in English.

Where the study is taking place: The study is conducted through a digital platform and is recruiting participants in the United States, with a study site located in Delafield, Wisconsin.

Study timeline: Recruitment is ongoing with an estimated enrollment of 10,000 participants; the study began in July 2023 and is expected to complete by the end of 2030.

Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms (https://clinicaltrials.gov/study/NCT04782830)

Trial number: NCT04782830

Overview: This study is investigating a new way to measure how well treatments for neurogenic orthostatic hypotension (a condition causing blood pressure to drop when standing) work by using an activity monitor to track time spent standing and walking during treatment and placebo weeks.

Who can participate: Adults aged 40 to 80 with certain neurological conditions causing neurogenic orthostatic hypotension, who are currently treated with midodrine or atomoxetine and still have symptoms, and who can stay with a caregiver during the study.

Where the study is taking place: The study is conducted at the Autonomic Dysfunction Center at Vanderbilt University Medical Center in Nashville, Tennessee, United States.

Study timeline: The study is currently recruiting, aims to enroll about 29 participants, started in February 2021, and is expected to complete by October 2027.

VCOM Pain Free Research Collaborative (https://clinicaltrials.gov/study/NCT06533345)

Trial number: NCT06533345

Overview: This study is observing different approaches to managing chronic pain, including behavior coaching, nutrition, physical treatments, and counseling, to help design a comprehensive pain clinic. Participants will receive various assessments and treatments based on these approaches.

Who can participate: Adults aged 21 to 80 who have ongoing chronic pain not related to recent injury can join, but those seeking drug treatments or with certain types of myofascial pain are excluded.

Where the study is taking place: The study is recruiting participants at Edward Via College of Osteopathic Medicine in Auburn, Alabama, United States.

Study timeline: The study began in August 2024 and is estimated to complete by August 2027, aiming to enroll about 120 participants.

VNS Prospective Neuromodulation of Immune and Gastrointestinal Systems (https://clinicaltrials.gov/study/NCT03953768)

Trial number: NCT03953768

Overview: This study is investigating how vagal nerve stimulation (VNS), a surgical treatment for epilepsy involving an implanted device that stimulates a nerve in the neck, affects the immune system and gut bacteria before and after surgery. Researchers aim to understand how VNS works outside the brain and identify markers that might predict its effectiveness.

Who can participate: People of any sex aged 0 to 60 who are having VNS implanted for epilepsy for the first time, have recent follow-up with a neurologist in Louisville or at specified sites, and can travel for outpatient care are eligible; certain health conditions and medications exclude participation.

Where the study is taking place: The study is recruiting participants at Norton Healthcare and University of Louisville in Kentucky, Texas Children’s Hospital in Houston, Texas, and Primary Children’s Hospital/University of Utah in Salt Lake City, Utah.

Study timeline: The study began in April 2021 and is currently recruiting, with an estimated enrollment of 30 participants; primary data collection is expected to complete by December 2025, and the study is estimated to finish by the end of 2026.

Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome (https://clinicaltrials.gov/study/NCT02602769)

Trial number: NCT02602769

Overview: This study investigates ROHHAD syndrome, a condition causing rapid weight gain and breathing problems in children, by examining patient-specific brain cells and their gene activity to better understand the causes of these symptoms. Some participants may also undergo detailed tests to study their metabolism.

Who can participate: Children aged 2 to 20 years diagnosed with ROHHAD syndrome can join, but those with known genetic causes of obesity are excluded.

Where the study is taking place: The study is conducted at Boston Children’s Hospital in Boston, New York, and Columbia University Irving Medical Center in New York, New York, United States.

Study timeline: The study is currently recruiting participants, aiming to enroll about 12 children, with an estimated start date in November 2015 and estimated completion in December 2026.